These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36033483)

  • 1. Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation.
    Su R; Chen L; Jiang Z; Yu M; Zhang W; Ma Z; Ji Y; Shen K; Xin Z; Qi J; Xue W; Wang Q
    Front Oncol; 2022; 12():955166. PubMed ID: 36033483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
    Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
    Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
    Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
    Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
    Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
    Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
    Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
    Nanda JS; Awadallah WN; Kohrt SE; Popovics P; Cates JMM; Mirosevich J; Clark PE; Giannico GA; Grabowska MM
    Prostate; 2020 Sep; 80(13):1058-1070. PubMed ID: 32692871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
    Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
    Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
    Bonkhoff H; Fixemer T
    Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor-neuroendocrine double-negative tumor with squamous differentiation arising from treatment-refractory metastatic castration-resistant prostate cancer.
    Sawazaki H; Asano A; Kitamura Y; Katsuta J; Ito Y
    IJU Case Rep; 2021 Nov; 4(6):417-420. PubMed ID: 34755072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
    Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.
    Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA
    Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
    Lee AR; Che N; Lovnicki JM; Dong X
    Front Oncol; 2018; 8():93. PubMed ID: 29666783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.